Musi wa16 Kurume, 2025, Akeso yakazivisa kuti mushonga wayo mutsva, wakazvigadzira wega, we anti-PD-1 monoclonal antibody, penpulimab, wabvumidzwa zviri pamutemo neNational Medical Products Administration (NMPA) wekurapa gomarara remumhino rinodzoka kana kuti rinopararira mumuviri pamwe chete nechemotherapy.
Penpulimab (PD-1 Monoclonal Antibody） parizvino ndiyo yega PD-1 monoclonal antibody yakasiyana inoshandisa IgG1 subtype neFc-nulldomain yakagadziriswa, iyo inogona kuwedzera kushanda kwe immunotherapy uye kuderedza maitiro ekudzivirira muviri. Inoshandiswa mukurapa zvirwere zvikuru zvakaita sekenza yemapapu, lymphoma, kenza yemhino, kenza yechiropa, uye kenza yemudumbu, nekuchengetedzeka kwakawedzerwa uye kushanda zvakanaka sezvakaratidzwa muzvidzidzo zvekiriniki.
Izvi zvinoratidza chiratidzo chechina chakatenderwa chepenpulimab. Pamusoro pezviratidzo zviviri zveNPC, penpulimab inotenderwawo kurapwa kwekutanga kwekenza yemapapu yemhando yepamusoro kana kuti metastatic squamous non-small cell lung cancer (NSCLC) kana ikasanganiswa nechemotherapy, pamwe nekurapa varwere vane relaxed kana refractory classical Hodgkin lymphoma (cHL) vakambogamuchira mishonga miviri ye chemotherapy. Uyezve, imwe nzira yekuwedzera yeNew Drug Application (sNDA) yepenpulimab pamwe chete neanlotinib yekurapa kwekutanga kwe advanced hepatocellular carcinoma (HCC) iri kuongororwa pari zvino.
Kare, penpulimab yaitenderwa kushandiswa senzira yekurapa yechitatu yeNPC yepamusoro. Nekubvumidzwa uku kutsva, penpulimab ikozvino inopa rubatsiro rwakakwana rwekurapa mumatanho ese eNPC, ichipa varwere sarudzo yekurapa immunotherapy inoenderera mberi kubva panzira yekutanga kusvika panzira yechitatu.
Musi wa19 Chikumi 2024, "Signal Transduction and Targeted Therapy" yakaburitsa mhedzisiro yechidzidzo chechikamu chechipiri pakurapa chirwere chekenza yemudumbu chakamborapwa nepembrolizumab.
Kuongororwa uku kwechikamu chechipiri chemuviri, kwakaitwa munzvimbo makumi maviri dzekurapa varwere muChina, kwakanyoresa varwere vakuru vane chirwere chekenza yemudumbu chakapararira (NPC) vakakundikana kurapwa nemishonga miviri kana kupfuura yekurapa chemotherapy. Varwere vakapihwa 200-mg yepenpulimab netsinga mavhiki maviri ega ega (mavhiki mana padenderedzwa) kusvika chirwere chaenderera mberi kana kuti chepfu dzisingatsungiririki. Mugumo wekutanga waive wekuti chirwere chiite sechiyero (ORR) paRECIST (vhezheni 1.1), sezvakaongororwa nekomiti yekuongorora radiology yakazvimirira. Mugumo wechipiri waisanganisira kupona kusina progression (PFS) uye kupona kwese (OS). Varwere zana nemakumi matatu vakanyoreswa uye 125 vakaongororwa kushanda zvakanaka. Pazuva rekupedzisira redata (Gunyana 28, 2022), murwere mumwe chete akawana mhinduro yakakwana uye varwere makumi matatu nevana vakawana mhinduro isina kukwana. ORR yaive 28.0% (95% CI 20.3–36.7%). Mhinduro yacho yaive yakasimba, ne66.8% vachiri kupindura mushure memwedzi mipfumbamwe. Varwere makumi matatu nevatatu (26.4%) vaive vachiri kurapwa. Pakati pePFS neOS zvaive mwedzi 3.6 (95% CI = mwedzi 1.9–7.3) uye mwedzi 22.8 (95% CI = mwedzi 17.1 zvisati zvasvika), zvichiteerana. Varwere gumi (7.6%) vakasangana ne irAEs dzegiredhi rechitatu kana kupfuura. Penpulimab ine mabasa ekudzivirira bundu uye chepfu inogamuchirwa muvarwere veNPC vakarapwa zvakanyanya, zvichitsigira kukura kwekiriniki sekurapa kwechitatu kweNPC yakapararira.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Kubvumbi-25-2025